* Sales rise 37 pct, oper profit up at 2.8 mln stg
* Gross profit up 43 pct at 14.5 mi
* Says Gen-Probe offer represents significant value
Feb 27 (Reuters) - Molecular diagnostics maker Tepnel Life Sciences Plc, which has agreed to be acquired by Gen-Probe, said on Friday full-year operating profit doubled on a 37 percent rise in revenue.
The company reported an operating profit of 2.8 million pounds ($4.01 million), compared with 1.4 million pounds in 2007 on revenue from continuing operations of 24.4 million pounds.
Gross profit rose 43 percent to 14.5 million pounds, while operating cash inflow increased to 4.2 million pounds from 1.7 million pounds year ago, the company added.
U.S. diagnostics firm Gen-Probe's 27.1 pence-per-share recommended offer represented significant value for Tepnel shareholders, the company said, adding that it had reached the agreement as it would require additional capital investment and access to certain technologies.
(Reporting by Ramkumar in Bangalore; Editing by Gopakumar Warrier) Keywords: TEPNELLIFE/
COPYRIGHT Copyright Thomson Reuters 2009. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
Datafeed and UK data supplied by NETbuilder and Interactive Data.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk!
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.